TD Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

TD Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-152	Closed	-$9K	–	156
2014 Q4	$9K	Hold	152	–	–	﹤0.01%	125
2014 Q3	$8K	Hold	152	–	–	﹤0.01%	124
2014 Q2	$8K	Buy	152 +1	+0.7%	+$51	﹤0.01%	130
2014 Q1	$8K	Hold	151	–	–	﹤0.01%	131
2013 Q4	$6K	Buy	151 +1	+0.7%	+$39	﹤0.01%	139
2013 Q3	$6K	Buy	150 +2	+1%	+$78	﹤0.01%	163
2013 Q2	$6K	Buy	+148	New	+$5.76K	﹤0.01%	173

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

TD Capital Management's TEVA Position: Q1 2015 in Review

TD Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 152 shares — an estimated $9K sold.

TD Capital Management first reported a position in TEVA in Q2 2013 and held it in 7 quarters. The position peaked at $9K in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

TD Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
TD Capital Management sold 152 Teva Pharmaceuticals shares in Q1 2015, an estimated $9K.
TD Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 7 quarters.
TD Capital Management's Teva Pharmaceuticals position peaked at $9K in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on TD Capital Management's 13F filing for Q1 2015, filed 7 May 2015.